Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0017160 (
gastroenteritis
)
11,398
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Cyclosporine (
Sandimmune
; Novartis Pharmaceuticals UK Ltd) is an effective immunosuppressive drug, but its lipid formulation and variable absorption may expose children to the risk of rejection during episodes of
gastroenteritis
after liver transplantation.
Neoral
(Novartis) is a microemulsified form of cyclosporine that may be better absorbed. In this study, the pharmacokinetic profiles of
Neoral
and
Sandimmune
were compared in stable children after liver transplantation to evaluate whether
Neoral
is more predictably absorbed. Eight children, 6 boys and 2 girls, with a mean age of 4.5 years (range, 1.2-12) were studied between 4 and 12 months after liver transplantation. Pharmacokinetic profiles were performed on each child by using the same dose (mg/kg) of
Neoral
or
Sandimmune
. Tmax, Cmax, Ctrough, and the area under the curve (AUC) were calculated and side effects were documented in children taking either drug for more than 3 months. Mean peak cyclosporine levels were higher and were achieved significantly sooner with
Neoral
(Cmax 790.5 +/- 216.5 ng/mL, P =.06; Tmax 1.8 +/- 1.0 hr, P =.01) than with
Sandimmune
(Cmax 589.4 +/- 313 ng/mL, Tmax 2.5 +/- 1.7 hr), implying more rapid and better absorption. There was no significant difference in overall drug exposure (AUC) and 12-hour trough levels between the two formulations (P >.05). Children with Roux-en-Y loop biliary anastomosis taking
Neoral
, however, showed greater increases in AUC (mean increase = 37%) than those with duct-to-duct anastomosis (mean increase = 16%). There was no correlation between 12-hour trough level and AUC for either
Neoral
(r2 = 0.48) or
Sandimmune
(r2 = -0.08); however, for both drugs, AUC correlated very well with the 2-hour post-dose level (r2 = 0.68 and 0.7, respectively). Hirsutism was reported in 4 of 6 children on
Neoral
and may be associated with higher peak levels.
Neoral
is more consistently absorbed than
Sandimmune
in children after liver transplantation and may be more effective prophylaxis against rejection. Because of the increased peak levels and drug exposure, which may influence side effects, particularly in children with
Sandimmune
malabsorption, we recommend a 1:0.75 dose conversion ratio in patients being converted from
Sandimmune
to
Neoral
.
...
PMID:Comparison of pharmacokinetics of Neoral and Sandimmune in stable pediatric liver transplant recipients. 1007 49